AI-Native Pharma: Rethinking the Value Chain from Molecule to Market

AI-Native Pharma: Rethinking the Value Chain from Molecule to Market
Intro image

Introduction

Pharma is at a pivotal moment. While AI-designed drugs are entering clinical trials, many companies remain stuck in outdated systems that stall innovation. Fragmented workflows, manual processes, and siloed AI pilots slow down R&D, regulatory approvals, and market access. To stay competitive, pharma must shift to an AI-native model, where intelligence is embedded across the entire molecule-to-market journey.

About the Whitepaper

This whitepaper explores how pharmaceutical companies can move beyond scattered AI efforts and legacy systems to become truly AI-native. It introduces a framework that integrates AI into every stage—from molecule discovery to commercialization—enabling faster trials, more intelligent decision-making, and real-world impact.

Discover how Straive’s five-pillar approach to AI-native transformation enables pharma enterprises to scale with confidence. The paper also features success stories from global pharma leaders and actionable insights on deploying AI to achieve measurable ROI.

Rethinking Pharma’s AI Roadmap: Why most AI pilots fail—and how an AI-native approach unlocks scalability, compliance, and tangible business outcomes.

Straive’s Five-Pillar Framework: A proven foundation built on unified data, explainable AI, human-AI synergy, governance, and scalable architecture.

Overcoming Real-World Barriers: How leading pharma firms break through data silos, workflow gaps, and low adoption to scale AI enterprise-wide.

Success Stories in Action: How Straive’s AI-native solutions reduced trial delays, automated regulatory processes, and accelerated global launches.

Download Whitepaper

Skip to content